A Phase I/II Study of Revlimid (Lenalidomide) in Combination With Vidaza (Azacitidine) in Patients With Advanced Myelodysplastic Syndrome (MDS).

Trial Profile

A Phase I/II Study of Revlimid (Lenalidomide) in Combination With Vidaza (Azacitidine) in Patients With Advanced Myelodysplastic Syndrome (MDS).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Feb 2013

At a glance

  • Drugs Azacitidine (Primary) ; Lenalidomide
  • Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Dec 2008 Results were presented at the 50th Annual Meeting of the American Society of Hematology.
    • 09 Dec 2008 Status changed from recruiting to completed according to a Celgene media release.
    • 09 Dec 2007 Preliminary results will be presented at ASH (abstract no. 1458) in December 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top